The effect of particle size on the dehydration/rehydration behaviour of lactose

International Journal of Pharmaceutics

Volumn 391, Issue 1-2, 2010, Pages 38-47

  Crisp, J L ^a   Dann, S E ^a   Edgar, M ^a   Blatchford, C G ^b  

^a LOUGHBOROUGH UNIVERSITY   (United Kingdom)

^b Health Care Ltd   (United Kingdom)

Author keywords

CP MASNMR; Lactose; Polymorph; PXRD; SEM; Sub micron

Indexed keywords

ALCOHOL; ALPHA LACTOSE; LACTOSE;

ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CONTROLLED STUDY; CRYSTAL; DESICCATION; DRUG STABILITY; DRUG SYNTHESIS; DRY POWDER; HYDRATION; INFRARED SPECTROSCOPY; PARTICLE SIZE; PRESSURE; PRIORITY JOURNAL; ROOM TEMPERATURE; SCANNING ELECTRON MICROSCOPY; SPRAY DRYING; SUSPENSION; WATER VAPOR; X RAY DIFFRACTION;

CRYSTALLIZATION; DESICCATION; DRUG STABILITY; ETHANOL; HUMIDITY; LACTOSE; NANOTECHNOLOGY; PARTICLE SIZE; POWDERS;

EID: 77952885171     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2010.02.012     Document Type: Article

References (28)

1. 2 supercritical antisolvent type process: comparison of different introduction devices. Ind. Eng. Chem. Res. 2009, 48:5671-5678.
2. Crowder T.M., Rosati J.A., Schroeter J.D., Hickey A.J., Martonen T.B. Fundamental effects of particle morphology on lung delivery: predictions of Stokes' Law and the particular relevance to dry powder inhaler formulation and development. Pharm. Res. 2002, 19:239-245.
3. Dunitz J.D., Bernstein J. Disappearing polymorphs. Acc. Chem. Res. 1995, 28:193-200.
4. Earl W.L., Parrish F.W. A cross-polarisatization-magic-angle sample spinning N.M.R. study of several crystal forms of lactose. Carbohyd. Res. 1983, 115:23-32.
5. Elajnaf A., Carter P., Rowley G. Electrostatic characterisation of inhaled powders: effect of contact surface and relative humidity. Eur. J. Pharm. Sci. 2006, 29:375-384.
6. Garnier S., Petit S., Coquerel G. Dehydration mechanism and crystallisation behaviour of lactose. J. Therm. Anal. Calorim. 2002, 68:489-502.
7. Giry K., Péan J.M., Giraud L., Marsas S., Rolland H., Wüthrich P. Drug/lactose co-micronization by jet milling to improve aerosolization properties of a powder for inhalation. Int. J. Pharm. 2006, 321:162-166.
8. Hein S., Picker-Freyer K.M., Langridge J. Simulation of roller compaction with subsequent tableting and characterization of lactose and microcrystalline cellulose. Pharm. Dev. Technol. 2008, 13:523-532.
9. Iida K., Inagaki Y., Todo H., Okamoto H., Danjo K., Luenberger H. Effects of surface processing of lactose carrier particles on dry powder inhalation properties of salbutamol sulfate. Chem. Pharm. Bull. 2004, 52:938-942.
10. Jinks, P.A., 2003. Preparation and utility of sub-micron lactose, a novel excipient for HFA MDI suspension formulations, Proc. DDL XIV.
11. Jinks, P.A., McKenzie, L., Lister, J.T., 2006. Medicinal aerosol formulations. Patent WO 2002/030394 (18.04.2002 gazette 2002/16).
12. Kirk J.H., Dann S.E., Blatchford C.G. Lactose: a definitive guide to polymorph determination. Int. J. Pharm. 2007, 334:103-114.
13. Larhrib H., Zeng X.M., Martin G.P., Marriott C., Pritchard J. The use of different grades of lactose as a carrier for aerosolised salbutamol sulphate. Int. J. Pharm. 1999, 191:1-14.
14. Larhrib H., Martin G.P., Prime D., Marriott C. Characterisation and deposition studies of engineered lactose crystals with potential for use as a carrier for aerosolised salbutamol sulfate from dry powder inhalers. Eur. J. Pharm. Sci. 2003, 19:211-221.
15. Lim S.G., Nickerson T.A. Effect of methanol on the various forms of lactose. J. Dairy Sci. 1973, 56:843-848.
16. Listiohadi Y., Hourigan J.A., Sleigh R.W., Steele R.J. Moisture sorption, compressibility and caking of lactose polymorphs. Int. J. Pharm. 2008, 359:123-134.
17. Maillard L.C. The action of amino acids on sugar; the formation of melanoidin by a methodic route. C. R. Hebd. Seances Acad. Sci. 1912, 154:66.
18. Malcolmson R.J., Embleton J.K. Dry powder formulations for pulmonary delivery. Pharm. Sci. Technol. Today 1998, 1:394-398.
19. Morgan K. Development of a preliminary framework for informing the risk analysis and risk management of nanoparticles. Risk Anal. 2005, 25:1621-1635.
20. Patel R.P., Baria A.H., Patel N.A. An overview of size reduction technologies in the field of pharmaceutical manufacturing. Asian J. Pharm. 2008, 216-220.
21. Perkins M.C., Bunker M., James J., Rigby-Singleton S., Ledru J., Madden-Smith C., Luk S., Patel N., Roberts C.J. Towards the understanding and prediction of material changes during micronization using atomic force microscopy. Eur. J. Pharm. Sci. 2009, 38:1-8.
22. Platteau C., Lefebvre J., Affouard F., Derollez P. Ab initio structure determination of the hygroscopic anhydrous form of α-lactose by powder X-ray diffraction. Acta Cryst. 2004, B60:453-460.
23. Platteau C., Lefebvre J., Affouard F., Willart J.F., Derollez P., Mallet F. Structure determination of the stable anhydrous phase of α-lactose from X-ray powder diffraction. Acta Cryst. 2005, B61:185-191.
24. Susi H., Ard J.S. Laser-Raman spectra of lactose. Carbohydr. Res. 1974, 37:351-354.
25. Tee S.K., Marriott C., Zeng X.M., Martin G.P. The use of different sugars as fine and coarse carriers for aerosolised salbutamol sulphate. Int. J. Pharm. 2000, 208:111-123.
26. Traini D., Young P.M., Thielmann F., Acharya M. The influence of lactose pseudopolymorphic form on salbutamol sulfate-lactose interactions in DPI formulations. Drug Dev. Ind. Pharm. 2008, 34:992-1001.
27. Zeng X.M., Martin G.P., Tee S.K., Ghoush A.A., Marriott C. Effects of particle size and adding sequence of fine lactose on the deposition of salbutamol sulphate from a dry powder formulation. Int. J. Pharm. 1999, 182:133-144.
28. Zeng X.M., Martin G.P., Marriott C., Pritchard J. Lactose as a carrier in dry powder formulations: the influence of surface characteristics on drug delivery. J. Pharm. Sci. 2001, 90:1424-1434.